Kaur S., Banerjee R.
Indian Institute of Technology - Bombay, IN
Keywords: aerosol, anti-angiogenic agent, combination therapy, lung cancer, nanoparticles
In the present study, we have conceptualized and formulated a novel delivery vehicle which includes a combination of lipid nanovesicles and polymeric nanoparticles. Main aim of the study is to devise a nanoscale platform technology for combination therapy to be given in aerosolized form for lung cancer treatment. A combination of hydrophobic chemotherapeutic agent and a hydrophillic anti-angiogenic agent is used in this study. Nanoparticles have been shown to have maximum deposition in the alveolar region and maintained the airway patency. A high loading of the drugs is attained in the nanoparticles and release kinetics are such that there is a burst release of the anti-angiogenic agent and a sustained release of paclitaxel. In vitro studies with lung cancer cell lines NCI-H460 and A549 have resulted in significantly low IC50 and high uptake of nanoparticles. The findings of the study suggest that this nanoscale system co-encapsulating a hydrophobic and a hydrophillic agent can be a potential candidate for lung cancer treatment via aerosol route.
Journal: TechConnect Briefs
Volume: 3, Nanotechnology 2013: Bio Sensors, Instruments, Medical, Environment and Energy (Volume 3)
Published: May 12, 2013
Pages: 411 - 414
Industry sectors: Advanced Materials & Manufacturing | Medical & Biotech
Topics: Biomaterials, Cancer Nanotechnology
ISBN: 978-1-4822-0586-2